The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback